Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15042893 | 0.86 | DHFR (0.41) | DHFRSLC2A1KIF11GABRA1GABRG2 | |
| SCHEMBL24804024 | 0.81 | CYP1A2 (0.47) | KIF11GABRA1GABRG2GABRB3HPGD | |
| SCHEMBL19737437 | 0.81 | DAO (0.50) | DHFRSLC2A1KIF11HPGDCYP1A2 | |
| SCHEMBL15042892 | 0.80 | DHFR (0.49) | DHFRSLC2A1KIF11GABRA1GABRG2 | |
| SCHEMBL16380970 | 0.79 | DAO (0.49) | DHFRSLC2A1KIF11HPGDCYP1A2 | |
| SCHEMBL16380899 | 0.79 | DAO (0.49) | DHFRSLC2A1KIF11HPGDALDH1A1 | |
| SCHEMBL16380895 | 0.79 | DHFR (0.48) | DHFRSLC2A1KIF11HPGDCYP3A4 | |
| SCHEMBL24447564 | 0.79 | RHEB (0.42) | DHFRSLC2A1KIF11HPGDALDH1A1 | |
| SCHEMBL24236481 | 0.77 | MEN1 (0.50) | DHFRSLC2A1CA1CA2 | |
| SCHEMBL21151024 | 0.77 | KIF11 (0.49) | DHFRSLC2A1KIF11GABRA1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2022083703-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR1, LPAR2, LPAR5 | DHFR 2241/4885SLC2A1 2023/4885KIF11 2621/4885 |
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | DHFR 3003/4885SLC2A1 3288/4885KIF11 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.